慢性丙型肝炎基因1型抗病毒治疗的进展  

Progress in antiviral treatment of chronic hepatitis C virus genotype 1 infection

作　　者：邓玲[1] 王小红[1] 

机构地区：[1]中国人民解放军第三军医大学西南医院感染病研究所,重庆市400038

出　　处：《世界华人消化杂志》2015年第27期4368-4375,共8页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.81171643~~

摘　　要：丙型肝炎病毒(hepatitis C virus,HCV)基因1型感染患者为难治型,聚乙二醇干扰素联合利巴韦林标准方案疗效欠佳.近来,直接抗病毒药物研制成功,陆续上市.第一代以N S3/4A蛋白酶抑制剂为主,但其仍需联合聚乙二醇干扰素及利巴韦林.随后,以NS5A抑制剂,NS5B聚合酶抑制剂为主的无干扰素方案陆续出现.Harvoni,VIEKIRA PAK等复合制剂已获得食品药品监督管理局(Food and Drug Administration,FDA)批准上市,这种高疗效、短疗程、不良反应小的直接抗病毒方案,为难治型患者和有干扰素及利巴韦林使用禁忌者带来希望.Hepatitis C virus（HCV） genotype 1 infection is difficult to treat,and the efficacy of peginterferon-α（PEG-IFN-α） and ribavirin（RBV） combination therapy is not very satisfactory.In recent years,direct-acting antiviral drugs（DAAs） have been developed and licensed for the treatment of HCV infection.The first-generation DAAs are NS3/4 polymerase inhibitors,which are often used in combination with PEG-IFN-α and RBV.Subsequently,some IFN-free regimens of NS5 A inhibitors and NS5 B polymerase inhibitors have shown promising results.Harvoni and VIEKIRA PAK have been approved by the United States Food and Drug Administration.These regimens have excellent response rates,short-duration and minimal toxicities and will bring hope to patients who are difficult to cure or with contraindications to the use of RBV or PEG-IFN-α.

关 键 词：丙型肝炎 基因1型 抗病毒 小分子化合物 

分 类 号：R512.63[医药卫生—内科学]